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Background: Arterial hypertension is highly prevalent but poorly controlled. Blood pressure (BP) reduction
substantially reduces cardiovascular morbidity and mortality. Recent randomized, double-blind clinical trials
demonstrated that azilsartan medoxomil (AZM) is more effective in reducing BP than the ubiquitary ACE inhibitor
ramipril. Therefore, we aimed to test whether these can be verified under clinical practice conditions.
Methods/Design: The “Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy” (EARLY)
registry is a prospective, observational, national, multicenter registry with a follow-up of up to 12 months. It will
include up to 5000 patients on AZM or ACE-inhibitor monotherapy in a ratio of 7 to 3. A subgroup of patients will
undergo 24-hour BP monitoring. EARLY has two co-primary objectives: 1) Description of the safety profile of
azilsartan and 2) achievement of BP targets based on recent national and international guidelines for patients
treated with azilsartan in comparison to those treated with ACE-inhibitors. The most important secondary
endpoints are the determination of persistence with treatment and the documentation of cardiovascular and renal
events. Recruitment commenced in January 2012 and will be completed by February 2013.
Conclusions: The data obtained will supplement previous results from randomized controlled trials to document
the potential value of utilizing azilsartan medoxomil in comparison to ACE-inhibitor treatment for target BP
achievement in clinical practice.
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Pressure Measurement, Central Systolic Blood PressureBackground
Arterial hypertension is a highly prevalent disease, sub-
stantially impacting cardiovascular prognosis [1]. Despite
the availability of many safe and effective antihyperten-
sive drugs, of which angiotensin converting enzyme
(ACE) inhibitors are the most widely used, blood pres-
sure (BP) is controlled in only 20% of hypertensive pa-
tients [2]. An additional reduction of mean systolic BP
in the order of 2 mmHg would result in a reduction of* Correspondence: gitta@klilu.de
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reproduction in any medium, provided the orthe rates of fatal stroke by 10% and of fatal myocardial
infarction by 7% [1]. There is clearly a need for drugs
that are potentially more effective and safe while having
a high tolerability and persistence rates.
Azilsartan medoxomil (AZM, TAK-491) is a recently de-
veloped angiotensin receptor blocker (ARB) that has a
number of specific characteristics [3]. It is structurally
similar to candesartan except that it bears a 5-oxo-1,2,4-
oxadiazolemoiety in place of the tetrazole ring [4]. Further
it has a carboxyl group at the 7-position of the benzimid-
azole ring, which is believed to result in insurmountable
receptor antagonism [3,5]. This insurmountable binding. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and long-lasting antihypertensive activity.Azilsartan - clinical efficacy, safety and tolerability
Four studies compared the clinical efficacy of AZM with
other ARBs. The studies included patients with primary
hypertension and used ambulatory BP monitoring
(ABPM) to determine BP lowering efficacy. AZM at a
dose of 80 mg once daily provided superior BP lowering
compared to the highest approved doses of olmesartan
(40 mg), valsartan (320 mg) and candesartan (32 mg)
[6-9] (Table 1).
Treatment was generally well-tolerated with a similar
rate of adverse events between AZM and placebo and low
rates of 2% to 3% for the withdrawal due to adverse events
[10]. The most frequent adverse event was diarrhea in up
to 2% of patients receiving the 80-mg dose compared with
0.5% of patients receiving placebo [10]. Other adverse
events included nausea, asthenia, fatigue, muscle spasm,
dizziness and cough. A small and reversible increase in
serum creatinine was observed in patients receiving AZM
80 mg. Low hemoglobin, hematocrit, and red blood cell
counts were observed only in 0.2%, 0.4%, and 0.3% of pa-
tients receiving AZM, respectively.
Recently, a randomized trial compared the antihyper-
tensive efficacy and safety of AZM to ramipril [11]. This
comparison is particularly important since ramipril is
considered a benchmark antihypertensive drug that has
not only been shown to be effective in lowering BP [12]
but also to reduce cardiovascular morbidity and mortal-
ity in patients at high risk in the landmark Heart Out-
comes Prevention Evaluation (HOPE) trial [13]. Patients
in this comparative trial were assigned to receive daily
doses of 40 mg AZM, 80 mg AZM or 10 mg ramipril.
The primary efficacy endpoint was the change in clinic
and ambulatory systolic BP from baseline. AZM 40 and
80 mg reduced both clinic and mean 24-hour systolic BP
significantly more than ramipril at a dose of 10 mg did
(clinic SBP −20.6 ± 0.9 with 40 mg and −21.2 ± 0.9 with
80 mg AZM vs. -12.2 ± 0.9 with ramipril) (Figure 1).
Adverse events leading to discontinuation of treatment
were less frequent with both doses of AZM (2.4% and
3.1%) compared with ramipril (4.8%).Aim of the registry
Based on these data, a considerable improvement of BP
control might be expected from using AZM in clinical
practice. The prospective observational registry (EARLY)
aims at documenting BP control and its impact on car-
diovascular and renal events during 12 months of
follow-up in patients with either AZM or ACE-inhibitor
treatment.Methods/Design
The “Treatment with Azilsartan Compared to ACE-
Inhibitors in Anti-Hypertensive Therapy” (EARLY) regis-
try is a prospective, observational, national, multicenter
registry with a follow-up of 12 months. The registry will
enroll up to 5000 patients with arterial hypertension
starting treatment on either AZM or any ACE inhibitor
monotherapy in up to 1000 sites in Germany in a ratio
of 7 (AZM) to 3 (ACE-inhibitors) (Figure 2). While BP
is regularly determined using office BP measurement,
there is a subgroup of patients with ABPM using the
Mobil-O-Graph® device. Data are recorded at baseline
and will be prospectively documented during follow-up
visits at 6 and 12 months or at the predefined end of the
registry in December 2013 (Figure 3).
The registry is conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki and adheres to the principles of Good Epidemi-
ology Practice (GEP), and applicable regulatory require-
ments. The protocol was approved by the independent
ethics committee in Freiburg and the ethics committee of
the State Medical Council of Rheinland-Pfalz, Germany.
EARLY has further been registered with the database of
the Verband forschender Arzneimittelhersteller (VFA). Pa-
tients being enrolled into this registry have to provide
written informed consent.
Objectives
EARLY has two co-primary objectives: 1) Description
of the safety profile of AZM. 2) Achievement of BP tar-
gets based on recent national and international guide-
lines for patients treated with AZM in comparison to
those treated with ACE-inhibitors.
Secondary objectives are as follows: 1) Absolute and
relative BP reduction with antihypertensive treatment
over the duration of one year. 2) Documentation of the
adherence to guidelines for the diagnosis and treatment
of hypertension in ambulatory care. 3) Persistence
understood as the mean duration of monotherapy and /
or AZM based combination therapy during follow-up. 4)
Documentation of adverse events. 5) Prospective docu-
mentation of cardiovascular and renal events. 6) A
pharmaco-economic evaluation of AZM use.
Additional objectives in a subgroup of patients with
ABPM are to document BP lowering and pulse pressure
reduction over the 1 year follow-up considering prior
and concomitant antihypertensive pharmacotherapy as
well as BP at baseline, and BP control with AZM in
comparison to ACE-inhibitors (specific ACE inhibitors
will be considered given their sample size is sufficient).
Second, BP values obtained from ABPM will be com-
pared to corresponding office BP values. Finally, central
systolic and diastolic blood pressure, cardiac output (per
minute), peripheral resistance, augmentation index, and
Table 1 Clinical trials conducted with Azilsartan to date (Phase III)
Duration Patients Intervention Primary endpoint Outcome
Sica et al. 2011 [7] 24 984 patients AZM 40 mg/d (n=327) Change in 24-hour AZM 40 mg/d: -14.9 mmHg
Mean age: 58 years AZM 80 mg/d (n=329) mean SBP from baseline to week 24 AZM 80 mg/d: -15.3 mmHg
Female: 48% Val 320 mg/d (n=328) Val 320 mg/d: -11,3 mmHg
BMI: 31 kg/m2 (p<0.001)
Race: 77% Caucasian
White et al. 2011 [6] 6 1291 patients AZM 40 mg/d (n=280) Change in 24-hourmean SBP from
baseline to week 24
AZM 40 mg/d: -13.4 mmHg
Mean age: 56 years AZM 80 mg/d (n=285) AZM 80 mg/d: -14.5 mmHg
(p=0.009 vs. OLM,
p<0.001 vs. VAL)Female: 46% Valsartan 320 mg/d (n=282)
BMI: 31 kg/m2 Olmesartan 40 mg/d (n=290) Valsartan 320 mg/d: -10.2 mmHg
Race: 65% Caucasian Placebo (n=154) Olmesartan 40 mg/d: -12.0 mmHg
Placebo: -0.3 mmHg
Bakris et al. 2011 [8] 6 1275 patients AZM 20 mg/d (n=283) AZM 20 mg/d: -12.2 mmHg
Mean age: 50 years AZM 40 mg/d (n=283) AZM 40 mg/d: -13.5 mmHg
Female: 50% AZM 80 mg/d (n=285) AZM 80 mg/d: -14.6 mmHg
BMI: 30 kg/m2 OLM 40 mg/d (n=282) (p=0.038 vs. OLM))
Race: 73% Caucasian Placebo (n=142) Change in 24-hour mean SBP from
baseline to week 6
OLM 40 mg/d:-12.6 mmHg
Placebo: -1.4 mmHg
Rakugi et al. 2012 [9] 16 622 patients Azilsartan up to 40 mg/d (n=313)
Change in sitting trough clinic DBP
from baseline to week 16 (LOCF)
Azilsartan: -12.9 mmHg
Mean age: 57 years Candesartan up to 12 mg/d (n=309) Candesartan: -9.7 mmHg
Female: 39% (p=0.0003)
BMI: 25.5 kg/m2 (SBP reduction at week 16: AZM –
Race: 100% Japanese 21.6 mmHg, CAN −17.3 mmHg)
Bönner et al. 2013 [11] 24 884 patients AZM 40 mg/d (n=295) Change in sitting trough clinic SBP
from baseline to week 24
AZM 40 mg: -10,2 mmHg
Mean age: 57 years AZM 80 mg/d (n=294) AZM 80 mg: -10,5 mmHg
Female: 48% Rami 10 mg/d (n=295) Rami 10 mg: -4,9 mmHg
BMI: 30 kg/m2 (clinic SBPp<0.001)
Race: >99% Caucasian
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Figure 1 Office blood pressure reduction in a comparative trial
of Azilsartan Medoxomil (AZM) and ramipril (RAM) [11].
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between patients receiving AZM or ACE-inhibitor
treatment.
Selection of sites
The registry is performed in primary care offices in
Germany, with a planned participation of up to 1000 sites.
Centers will be selected from a database maintained at the
Institut für Herzinfarktforschung, Ludwigshafen, in order
to be representative for the ambulatory treatment of
hypertension in Germany. The recruitment per physician
is limited to a maximum of 30 patients.
Selection of patients
Adult patients (≥ 18 years) with essential arterial hyper-
tension are included on a consecutive basis, given they
have provide written informed consent and fulfill the
following two criteria: 1) Participants have either no
anti-hypertensive treatment prior to inclusion or a prior
non-RAS based antihypertensive monotherapy. 2) A
monotherapy using AZM or any ACE-inhibitor is initi-
ated at baseline.Consecutive patients 
monotherapy or bein
N = 5.0





Figure 2 Principal design of EARLY. Patients will be recruited on a conse
defined, in a ratio of 7 (AZM) to 3 (ACE inhibitors).Patients are excluded from participation if they 1) re-
ceive antihypertensive drugs for an indication other than
hypertension (e.g. beta blockers or diuretics for heart
failure), 2) have a history of alcohol, drug abuse or illegal
drug addiction, 3) have a life expectancy of less than one
year, 4) are pregnant or breast feeding, or 5) are partici-
pating in other trials or registries. Further to this, pa-
tients with contraindications as to the summary of
product characteristics of AZM or the ACE inhibitors
will not be permitted. Patient recruitment started in
January 2012 and will end on February 28th 2013 at the
latest or as soon as the recruitment target of 5000 pa-
tients is met.
Documented variables
Table 2 displays the variables documented at baseline
and at the follow-up visits at 6 and 12 months. These
include socio-demographic variables, BP / heart rate,
anamnestic concomitant disease, risk factors, anti-
hypertensive treatment including dose, further pharma-
cotherapy, investigations, laboratory values, incident
concomitant disease, lethal and non-lethal event rates
and adverse events. In the subgroup of patients with
ABPM respective parameters will be documented.
Quality assurance
There are three strategies for data quality checks: valida-
tions that occur at the time of data entry (i.e., “front-
end”), a second, more sophisticated quality control
program that runs as a prelude to the creation of the
analysis data set and on-site data monitoring. Front-end
data checks are advantageous because mistakes are
caught and corrected at the time of entry – a system
that is efficient for data collectors. Certain data elements
can be required, while other variables may allow for
missing values. Additionally, parameters will be defined
to allow entry of only those records that meet inclusion
criteria. Prior to the creation of the analytic dataset,
more extensive quality control processes are performed.
These checks, programmed in SAS, include parent–child
edits, consistency edits, and data transformations thaton anti-hypertensive 
g treatment naive 
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Figure 3 Patient recruitment and follow-up.
Table 2 Variables documented at baseline, and at 6 and







Socio-demographic variables 1 X X9 X9
Blood pressure / heart rate X X X
Anamnestic concomitant disease 2
X
Risk factors 3 X
Anti-hypertensive treatment incl. dose
X X X
Further pharmacotherapy 4 X X X
Further investigations 5 X
Laboratory values 6 X X X
ABPM 7 (subgroup) X X X
Event rate (lethal / non-lethal) X X
Incident concomitant disease 8 X X
Adverse events X X
Legend:
1) age, gender, height, weight, body mass index (computed).
2) heart failure (including NYHA class), coronary artery disease, stroke /
transitory ischemic attack, atrial fibrillation, peripheral arterial disease, diabetes
mellitus (including duration), kidney disease (including glomerular filtration
rate <60 ml/1.73m2, dialysis or transplantation), malignancy, chronic
obstructive pulmonary disease, depression and other severe diseases.
3) hypercholesterolemia, hyperlipidemia, smoking (present, past or never,
including duration).
4) other than antihypertensive drugs: nitrates, platelet aggregation inhibitors,
oral anticoagulants, statins or antidepressive drugs.
5) signs of left ventricular hypertrophy (ECG or Echo), intima / media thickness
> 0.9 mm or plaque, ankle-brachial index (ABI) < 0.9, pulse wave velocity > 12
ms, microalbuminuria.
6) hemoglobin, glucose, bA1c, creatinine, sodium, potassium, calcium,
phosphate, total cholesterol, LDL-C, HDL-C, triglycerides, C-reactive protein,
uric acid, urinary albumin concentration and albumin to creatinine ratio (all if
available within three months prior to visit.
7) mean blood pressure and heart rate during daytime, nighttime and
24-hour average.
8) corresponding to 2) including whether patients were hospitalized and for
how long.
9) weight only.
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accuracy will be verified by site visits in randomly se-
lected 5% of the sites.
Data management and statistics
Data entry is performed by the physician or study nurse
via a secure website directly into an electronic database.
This approach allows online checks for plausibility and
integrity.
The sample size for this registry was determined
aiming to provide a sufficient precision of the primary
endpoint, e.g. BP target achievement of <140/90 mmHg
with a monotherapy of AZM or an ACE-inhibitor. Based
on the aforementioned trial published by Bönner et al.
[11] comparing AZM with the ACE-inhibitor ramipril,
target achievement rates of 50-60% can be expected with
AZM monotherapy versus 30-40% with ramipril. Be-
cause of the two principal research objectives
each confidence interval (CI) is determined using the
Bonferroni method for the adjusted confidence probabil-
ity (1–0.05/2). For the AZM group a precision of the
determined control rate of ±2.1% is planned (width of
the 97.5% CI 4.2%), while a ±3.2% precision is deemed
sufficient for the ACE-inhibitor arm. For this purpose
2849 patients have to be recruited for the AZM arm and
1178 patients for the ACE-inhibitor arm. Considering a
design effect of 1.15 (because of the cluster-sampling de-
sign and allowing a drop-out of 5%), 3500 patients have
to be recruited for the AZM and 1500 patients for the
ACE-inhibitor arm, resulting in a total population of
5000 patients. There will be a proportional recruitment
of patients until February 28th 2013. In case the recruit-
ment target of 5000 patients is not met, a reduced preci-
sion of the primary objective will be accepted.
All variables collected in the eCRF as well as the data
obtained from the quality of life assessments and all de-
rived parameters will be used in the statistical analysis.
Binary, categorical, and ordinal parameters will be sum-
marized by means of absolute and percentage numbers
within the various categories (including ,,missing data‟
as valid category at baseline). Numerical data will be
summarized by means of standard statistics (i.e. number
of available data, number of missing data, mean, stand-
ard deviation, minimum, median, maximum, lower andupper quartile). In addition, adequate graphs (e.g. bar
charts, box-whisker plots) may be presented to
summarize the results for some parameters. Time-to
-event variables will be analyzed via a Cox proportional
hazard regression model presenting hazard ratios and
the corresponding 95% confidence intervals (CI). In
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variables. Two-sided 95%-CI will be presented for im-
portant parameters, but should be interpreted in an ex-
ploratory descriptive way. Further multivariable analyses
will be performed according to the statistical analysis
plan (SAP). Formal statistical tests will not be performed
within the statistical analysis. A report including descrip-
tive statistics of all documented parameters will be gen-
erated for the overall patient population. Depending on
the variable(s) of interest, additional selection criteria for
patients (e.g. subgroup analyses) considered in specific
analyses may be used, if considered useful during the
statistical analysis. Details on the selection criteria used
will be given in the SAP and in the statistical section of
the report. The statistical analysis will be performed
using SAS (release 9.2 or higher; Cary, NC, USA).
Discussion
Value of non-interventional studies
Non-interventional studies supplement the results from
randomized clinical trials (RCT) because they include
patients that are frequently excluded from clinical trials
because of stringent in- and exclusion criteria, thus
representing clinical practice. This has been exemplified
based on the “Global Registry of Acute Coronary Events”
(GRACE registry) [14]. For this analysis 8469 patients
were classified into three groups: included into contem-
porary RCTs (n=953), those eligible but not included
(n=4669) and patients not eligible (n=2847). It was
found that RCT participants had the lowest risk of
death, eligible but not included had a higher risk and in-
eligible patients had the highest risk. Actual hospital
mortality showed a similar gradient (3.6%, 7.1%, and
11.4%, respectively).
Similar observations were made in the recent non-
interventional study SERVE [15]. Out of 8086 patients
enrolled, only 2222 would have been eligible for the cor-
responding RCT COACH, based on the defined in- and
exclusion criteria [16]. This led to an underestimation of
the true BP lowering effect compared to the real life
situation. It has to be acknowledged, however, that while
the external validity of non-interventional studies is
high, the internal validity is usually lower than in a RCT.
For the particular comparison of ARB with ACE-
inhibitor treatment the EARLY registry is pursuing,
available data is limited. This is mostly because non-
interventional studies usually have no control group and
are single-armed studies. If the results of a comparison
are presented these mostly relate to differences between
ARB treatment versus a stopped ACE-inhibitor at base-
line. A more recent retrospective analysis by Roy and
colleagues [17] used propensity score matching to bal-
ance two groups of patients receiving a new prescription
of either ACE-inhibitors or ARBs on baseline factors. Atotal of 25035 patients were identified. No differences
were found in the risk of death, coronary disease,
chronic kidney disease, or stroke between those pre-
scribed ACE-inhibitors or ARBs except for a higher rate
of diabetes in patients treated with ARBs.
Ambulatory BP monitoring substudy
There is a substudy in EARLY utilizing ABPM to verify
and enhance diagnostic accuracy and add values not
regularly obtained during office BP measurement. This
is of particular importance since it has been shown that
reductions in office-based BP values cannot to be trans-
lated 1:1 to 24-hour BP values. This was shown in a re-
cent study in which lercanidipine was compared with
enalapril in daily practice [18] using office (OBPM),
ABPM and self measurement (SBPM). BP reductions de-
rived from OBPM correlated to the values derived from
SBPM and ABPM (day) at follow-up. However, correl-
ation coefficients were usually low (range 0.05 -- 0.26)
with highest coefficients for the correlation between SBP
measured by OBPM and SBPM (r = 0.26). Lowest corre-
lations were observed for OBPM and ABPM (r = 0.05
for SBP reductions). Higher values were seen in a further
non-interventional study comparing OBPM and ABPM
in patients receiving candesartan [19]. Correlation be-
tween OBPM and ABPM was substantially better with
r = 0.589 for SBP and r = 0.389 for DBP during the day.
In addition to the brachial blood pressure measure-
ments, the use of the mobilograph device allows to
analyze the treatment induced changes of the central
systolic blood pressure and pulse pressure as well as the
augmentation index. Thus, we are able to examine the
effects of AZM on central hemodynamic and vascular
stiffness of large arteries.
Limitations
There are a number of potential limitations to the design
of the EARLY registry. Although we have a control
group of patients receiving ACE-inhibitors, allowing to
compare effectiveness and tolerability between AZM
and ACE-inhibitors we have an 1) imbalance in group
size, that will allow to determine control rates with
AZM more precisely than in the control group. 2) The
assignment to AZM or ACE-inhibitor treatment is
performed by the treating physician and not the result of
randomization. 3) Only a limited number of the available
ACE inhibitors (e.g. ramipril) will be allowed because
prescription rates of some of the other ACE inhibitors
may be low. 4) Patients selected for AZM treatment may
differ for known or unknown reasons from those receiv-
ing ACE inhibitor treatment. These limitations have to
be weighed against the potential implications of EARLY
findings: the registry includes a large group of unselected
patients in primary care without the limitation given by
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follow-up that will allow to determine whether differ-
ences in BP lowering efficacy, persistence with treatment
and tolerability might translate into a reduction of
events throughout follow-up.
Conclusions
The data obtained will supplement previous results from
randomized controlled trials to document the potential
value of utilizing azilsartan medoxomil in comparison to
ACE inhibitor treatment for target BP achievement.
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